Key Takeaways Successful late-stage trials and a durable eye disease treatment position the company for strong physician adoption and significant revenue growth upon approval. Strategic expansion, robust manufacturing, and disciplined financial management lower risk and enable long-term pipeline and market opportunity development.Read more
Key Takeaways EyePoint's rapid clinical execution, manufacturing readiness, and global strategy position it for unmatched early market penetration and accelerated revenue growth ahead of competitors. Proprietary sustained-release technology, expanding indications, and demographic trends provide strong long-term revenue visibility, risk diversification, and enhanced attractiveness for strategic partnerships.Read more
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company’s pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
